San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
Method of more easily growing hair cells is announced by Sanford-Burnham scientists.
Researchers develop new probe to measure MALT1 activity that may improve diagnostic and therapeutic tools for autoimmune disorders.
Aspyrian Therapeutics Inc., a San Diego-based biotechnology startup, has raised $8.45 million in equity financing, according to a recent filing with the Securities and Exchange Commission.
To better understand PLA2 enzymes and help drive therapeutic drug development, researchers at University of California, San Diego School of Medicine developed 3D computer models that show exactly how two PLA2 enzymes extract their substrates from cellu…
The San Diego Supercomputer Center (SDSC) at the University of California, San Diego is a partner in a new international collaboration to develop computational models and software for simulations of bifunctional catalysis, which is of hi…
San Diego biotech’s gravitational pull brings in companies and people from elsewhere.
For the second time in five years, CSE Prof. Victor Vianu is the recipient of the ACM PODS Alberto O. Mendelzon Test-of-Time Award. The annual award goes to the author or co-authors of a paper published in the proceedings of the Principl…
In 2015, look for the innovation community to be talking about Big Data Variety: the problem, how to fix it, how to make money off of it. Companies have invested roughly $3-4 trillion on enterprise…
[[Click headline to continue reading.]]
Trovagene’s Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview at the Personalized Medicine World Conference
MOUNTAIN VIEW, Calif., Jan. 26, 2015 /PRNewswire/ — Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Chief Scientific Officer, Mark Erlander, Ph.D., will present an overview of the Company’s Precision Cancer MonitoringSM platform during the 2015 Personalized Medicine World Conference in Silicon Valley. Erlander’s presentation, titled “Quantitative Detection of Cancer Mutations in Liquid Biopsy Samples,” will be delivered today, during Track 1 at 11:15 a.m. PST.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s Precision Cancer MonitoringSM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.
David Moskowitz and Amy Caterina
Canale Communications, Inc.
SOURCE Trovagene, Inc.
Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers
SAN DIEGO, Jan. 26, 2015 /PRNewswire/ — Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which is taking place at the Computer History Museum in Mountain View, Calif. on January 26-28, 2015.
Dr. Prahalad will give a presentation entitled, “CTCs Come of Age as Biomarkers.” Last year, Epic Sciences was a finalist in the PMWC’s Most Promising Company Award Competition.
The details of the presentation are as follows:
Date: Tuesday, January 27, 2015
Track 1: Applying Complementary Technologies Towards Biomarker Discovery
Time: 3:45 PM PST
Co-hosted with Stanford Health Care and Oracle in Silicon Valley, PMWC 2015 will gather close to 1,000 multidisciplinary attendees and key stakeholders from the business, government, healthcare delivery, research and technology arenas to examine the advances and challenges of personalized medicine through a practical lens.
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic’s no cell left behind™ technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
SOURCE Epic Sciences